| Abstrakt: |
Aim: We sought to define the degree of NAFLD with B-mode ultrasound sono-elastography using the discriminant Bonacini scale in type 2 diabetes (T2D) patients. Materials and Methods: Forty-three patients with T2D and clinically diagnosed NAFLD (26F, 17M) were examined with liver ultrasound in B-mode elastography. The presence and degree of fibrosis was assessed using the Bonacini Classification (Discriminant) Scale. The compliance of the stage of the fibrosis was compared with results of the histological evaluation of METAVIR and Ishak. Results: An enlarged liver was found in all, often combined with the hyperechogenic, coarse-grained structure. In rare cases, a decrease in the liver echogenicity indicated development of fibrosis. The liver density index was significantly higher in men (2.63 ± 0.05) than in women (2.49 ± 0.06, p = 0.05). In a series of correlation analyses, it was found that sono-elastography strongly correlated with the results of the classification (discriminant) Bonacini score scale (r= 0.68 ± 0.13, p <0.001). The results of the Ishak and METAVIR scales at minimum values have a moderate correlation with sono-elastography data (r= 0.36 ± 0.17, p < 0.05 and r= 0.37±0.16, p<0.05respectively). These scales determine the degree of fibrosis as a range from the less to the greater degree, but the stronger correlation (r= 0.50 ± 0.16, p<0.01and r= 0.47 ± 0.15, p<0.01respectively) with results of sono-elastography was found in patients with severe fibrosis of the liver. Conclusion: In majority of type 2 DM patients with clinical NAFLD a slight degree fibrosis (F0-F2) was diagnosed. To better assess the degree of liver fibrosis in these patients it is advisable to use sono-elastography and the discriminant Bonacini scale. These have similar significance, can complement each other and allow identification of early manifestations of liver fibrosis in patients with type 2 DM. Disclosure: O. Lavrynenko: None. O. Zemlianitsyna: None. N. Kravchun: None. I. Dunaeva: None. I. Karachentsev: None. V. Sinaiko: None. R.A. DeFronzo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Elcelyx Therapeutics, Inc., Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc. Research Support; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc. Speaker's Bureau; Self; AstraZeneca, Novo Nordisk Inc. E. Cersosimo: None. [ABSTRACT FROM AUTHOR] |
